Navigation Links
Par Pharmaceutical Begins Shipment of Generic Zegerid®
Date:7/1/2010

WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus’ Zegerid®. Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for these strengths of the product.

On April 14, 2010, the District Court of Delaware held that the patents covering Zegerid are invalid. The case is currently on appeal at the Court of Appeals for the Federal Circuit.

Important information about omeprazole and sodium bicarbonate capsules

Omeprazole and sodium bicarbonate is a combination of omeprazole, a proton-pump inhibitor, and sodium bicarbonate, an antacid.  

Omeprazole and sodium bicarbonate is indicated for the short-term treatment of duodenal ulcer, the short-term treatment (4-8 weeks) of active benign gastric ulcer, the treatment of heartburn and other symptoms associated with Gastroesophageal Reflux Disease (GERD) and short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K in other of the Company’s filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
2. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
3. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
4. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
5. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
6. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
8. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
9. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
10. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
11. Jazz Pharmaceuticals JZP-6 to be Reviewed at a Joint Meeting of the FDAs Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on August 20, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... programs. The hands-on learning experience is a 12-week summer ... Fellowship and Internship programs bring ... and interns are provided optional housing free of charge ... at the Riverfront Residence Hall to foster communication and ...
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... WASHINGTON , May 23, 2016 The World ... PrePex device to include adolescents aged 13 years, ... MedTech, can be offered for adult and adolescent males in ... Africa . PrePex was the first male circumcision device ... Circ MedTech,s CEO, Eddy Horowitz said: " The ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 25, 2016 , ... Today American University of Antigua (AUA) ... announced the AUA-FIU Global MD Program. Students in the Global MD Program ... a Certificate of Completion from the FIU Herbert Wertheim College of Medicine Clinical ...
(Date:5/25/2016)... ... ... Today Omega Institute, a leading destination for yoga education in New York’s Hudson ... the growing field of yoga therapy . Yoga therapy adapts the practice of ... injuries, illnesses, and temporary or chronic health conditions. , “Yoga therapy is a complementary ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit (GWS) today announced ... wellness offerings of Europe, a continent that pioneered the medical/wellness concept for the world. ... pioneers in medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering comprehensive ... Prescription Drug survey , an employee benefits survey measuring how Central ... December 2015, indicates that employers are turning to consumer directed health care and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & ... turn back the hands of time of female aging. The Juliet™ ... Women with symptoms such as leakage, laxity, itchiness and pain have reported real relief ...
Breaking Medicine News(10 mins):